461 reports of this reaction
3.4% of all CLADRIBINE reports
#3 most reported adverse reaction
LYMPHOCYTE COUNT DECREASED is the #3 most commonly reported adverse reaction for CLADRIBINE, manufactured by EMD Serono, Inc.. There are 461 FDA adverse event reports linking CLADRIBINE to LYMPHOCYTE COUNT DECREASED. This represents approximately 3.4% of all 13,464 adverse event reports for this drug.
Patients taking CLADRIBINE who experience lymphocyte count decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
LYMPHOCYTE COUNT DECREASED is moderately reported among CLADRIBINE users, representing a notable but not dominant share of adverse events.
In addition to lymphocyte count decreased, the following adverse reactions have been reported for CLADRIBINE:
The following drugs have also been linked to lymphocyte count decreased in FDA adverse event reports:
LYMPHOCYTE COUNT DECREASED has been reported as an adverse event in 461 FDA reports for CLADRIBINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
LYMPHOCYTE COUNT DECREASED accounts for approximately 3.4% of all adverse event reports for CLADRIBINE, making it one of the most commonly reported side effect.
If you experience lymphocyte count decreased while taking CLADRIBINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.